Business Wire

Uptime’s 13th Annual Global Data Center Survey Shows Widening Range of Challenges

18.7.2023 13:03:00 EEST | Business Wire | Press release

Share

Uptime Institute today announced the release of its 13th Annual Global Data Center survey. The findings show data center operators facing stricter regulations and more pressure to reduce energy, along with persistent staffing and supply chain issues. The Report shows new technologies potentially presenting a promising way forward, but these often are found lacking in standardization and scalability. While for many organizations, investments in efficiency and resiliency are beginning to pay off, progress has been gradual.

“Our data shows operators grappling with several issues,” said Andy Lawrence, executive director, Uptime Intelligence. “In 2023, the lingering effects of the COVID-19 pandemic have receded, but other challenges have emerged. Digital infrastructure managers are now most concerned with improving energy performance and dealing with staffing shortfalls, while Government regulations aimed at improving data center sustainability and visibility are beginning to require attention, investment, and action.”

Uptime’s Annual Global Data Center survey is the largest, most comprehensive, and longest-running study in the digital infrastructure sector. It provides detailed insights into the digital infrastructure landscape and a view into its future trajectory. Key findings from the 2023 report include:

  • Average global power usage effectiveness (PUE) levels have remained flat for four years. Additional improvements in PUE levels will require significant investment.
  • As more organizations opt for a hybrid approach to IT, the share of enterprise workloads that are run in corporate, on-premises facilities has fallen to below half for the first time and is expected to shrink further.
  • Enterprise operators say data security is the biggest impediment to moving mission-critical workloads to the public cloud. Resiliency and transparency are lesser concerns.
  • Server rack densities are climbing steadily, but slowly. Average rack densities are below 6 kilowatt (kW) per rack; most operators do not have any racks beyond 20 kW. This suggests the widespread use of direct liquid cooling is not imminent.
  • Many operators only collect a limited amount of sustainability related data and will struggle to meet emerging sustainability reporting requirements, or in turn, the requirements of some customers and the public.
  • Most operators believe acceptance of the use of artificial intelligence will grow in data centers, but operators are distrustful of its ability to make reliable operational decisions.

Outages:

  • More than half (55%) of operators reported they have had an outage at their site in the past three years, the lowest number yet recorded. This continues a trend of steady improvement.
  • Power outages continue to be cited as the single biggest cause of outages.

Staffing:

  • Uptime Intelligence data shows that approximately 8% of the data center workforce are women. In the US (if not all countries), this rate is below that of other male-dominated industries, such as mining and construction.
  • Nearly two-thirds of operators have problems recruiting or retaining staff – however, this figure is not currently growing. The largest skill gaps are in operations, mechanical and electrical roles.

About the Survey:

Uptime conducted this year’s annual Global Data Center Survey online from February – April 2023 and collected responses from more than 850 data center owners and operators and nearly 700 vendors and consultants.

Learn More:

Uptime’s 2023 Global Data Center Survey also includes findings on regulatory support, sustainability, and metrics, staffing shortfalls, skills gaps, diversity, innovation and impact, and more. Download the executive summary report here and register for the webinar covering its key trends and takeaways on July 18th at 12:00 PM EDT, 5:00 PM BST.

About Uptime:

Uptime Institute is the Global Digital Infrastructure Authority. For over 25 years, the company has established industry-leading benchmarks for data center performance, resilience, sustainability, and efficiency, which provide customers assurance that their digital infrastructure can perform across a wide array of operating conditions at a level consistent with their business needs. Uptime’s Tier Standard is the IT industry’s most trusted and adopted global standard for the design, construction, and operation of data centers. With its Tier Standard and Certifications, Management & Operations reviews, SCIRA-FSI financial sector risk assessment, broad range of additional risk and performance assessments, intelligence research service, and training courses completed by over 10,000 data center professionals, Uptime has helped thousands of companies in over 114 countries to optimize critical IT assets while managing costs, resources, and efficiency.

Uptime Institute is headquartered in New York, NY, with offices in London, Sao Paulo, Dubai, Riyadh, Singapore, and Taipei. For more information, please visit www.uptimeinstitute.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Brenda South
206/706-4647
bsouth@uptimeinstitute.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release

Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye